Fig. 1

Temporal tumour cell biology impacts MRBV oncolytic efficacy in vitro. a. Serum CA-125 concentration (units per mL) for the patient from whom ascites samples were collected to derive new cell lines from October 2008 to March 2012 comprising the complete clinical course of her disease. iOvCA105, iOvCa131, iOvCa142, and iOvCa147 samples were derived from multiple ascites isolated upon first relapse and over a 14-month period (upward arrows). iOvCa105 cells were isolated October 2010 after first relapse with platinum-sensitive disease. iOvCa131, iOvCa142, and iOvCa147 were collected in close succession one year later between October 2011 and December 2011 upon second recurrence and acquisition of platinum resistance. b. Cells from all four cell lines were seeded at 10,000 cells per well of a 96-well plate and infected with different doses of MRBV as indicated, or UV-inactivated MRBV as a control. Cells were assayed for viability using CellTiter-Glo® reagent at 72 h post-infection. (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001, as determined by one-way ANOVA and Dunnett’s posthoc test)